Lisocabtagene Maraleucel
VIDEO: ‘Plenty of options out there’ for relapsed/refractory CLL treatment
In a video interview, Matthew Cortese, MD, MPH, discusses advances in treatments for relapse/refractory CLL.
VIDEO: Tailoring initial treatment approach for CLL to patients’ molecular features
In a video interview, Matthew Cortese, MD, MPH, discusses how to approach initial treatment of CLL.
Oncologists pleased with new treatments for lymphoma, lung cancer, urothelial cancer
FDA approves Breyanzi CAR-T for follicular lymphoma
The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of adults with relapsed or refractory follicular lymphoma who received at least two prior lines of systemic therapy.
FDA approves Breyanzi CAR-T for chronic lymphocytic leukemia, small lymphocytic lymphoma
The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
FDA requires boxed safety warning for all CAR T-cell therapies
The FDA has requested manufacturers of commercially available chimeric antigen receptor T-cell therapies now include a boxed safety warning regarding the risk for secondary T-cell malignancies on prescribing labels.
FDA official says CAR-T ‘incredibly beneficial’ despite secondary malignancy risk
Benefits of chimeric antigen receptor T-cell therapy far outweigh the risks involved, including secondary T-cell malignancies, according to Peter Marks, MD, PhD, director of the FDA’s Center for Biologic Evaluation and Research.
Liso-cel CAR-T cost-effective as second-line treatment for advanced lymphoma
Researchers found lisocabtagene maraleucel to be a cost-effective second-line treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma, study findings published in Blood Advances showed.
CAR-T vs. bispecifics for lymphoma: Using the evidence to sequence treatments
Curative potential at a longer follow-up, logistics and patient risk and eligibility are all important considerations when sequencing bispecific antibodies and chimeric antigen receptor T-cell therapy for advanced large B-cell lymphoma.
VIDEO: Longer follow-up on CAR T-cell therapy for DLBCL shows durability and tolerability
In this video, Brian T. Hill, MD, PhD, discusses results of the phase 2 PILOT study of lisocabtagene maraleucel as second-line therapy for relapsed/refractory diffuse large B-cell lymphoma.